ArticleAnnals of medicine2025
Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe GEMSTONE-303 trial demonstrated that sugemalimab combined with capecitabine and oxaliplatin (CAPOX) improved survival benefit in patients with advanced gastric/gastroesophageal junction cancer (GC/GEJC) and a programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥5. However, its cost-effectiveness in China remains unassessed.
methodsA partitioned survival model was developed from the Chinese healthcare payer perspective using data from the GEMSTONE-303 trial. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were evaluated over a 10-year horizon. Sensitivity analyses assessed model uncertainty, while subgroup and scenario analyses examined the impact of PD-L1 expression, drug pricing, and patient assistance programs (PAPs).
resultsIn the PD-L1 CPS ≥ 5 group, sugemalimab plus CAPOX yielded an incremental cost of $44,455.46 and 0.22 additional QALYs compared to chemotherapy, resulting in an ICER of $206,024.50/QALY. For patients with CPS ≥10, the ICER dropped to $173,182.90/QALY, but still exceeded the willingness-to-pay (WTP) threshold. One-way sensitivity analysis revealed sugemalimab price as the most influential parameter, requiring a 75.6% price reduction to achieve cost-effectiveness. A PAP reduced ICERs to $44,926.00/QALY and $39,513.96/QALY in the CPS ≥5 and CPS ≥10 subgroups, respectively.
conclusionAt current prices, sugemalimab plus CAPOX is not cost-effective as a first-line treatment for advanced GC/GEJC in China. It is essential to adopt a combination of targeted patient selection, price negotiation, and broader PAP access to bring the ICER below the WTP threshold. These findings inform reimbursement negotiations and highlight the need for stratified pricing strategies to optimize accessibility in economically diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.